Study on Immune Status of Patients With COVID-19

COVID-19 Clinical Trial

Official title:

Study on Immune Status of Patients With COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05682573
• Other study ID #: Qilu-20230105-pang
• Status: Recruiting
• Start date: January 5, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2023
• Source: Qilu Hospital of Shandong University
• Contact: yuguo Chen, Dr
• Phone: +8618678812777
• Email: chen919085[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a prospective cohort study aimed to clarify the continuous immune state changes of patients with COVID-19. Investigators include the patients admitted to the hospital within one week after the onset of COVID-19. 10ml of patients' blood was collected day 1, day 7, day 14 , and day 20 after the patients admitted to the hospital. The blood inflammatory factors, immune related molecules, and immune cells were detected to determine the changes of patients' immune status. The impact of immune status changes on prognosis and quality of life in later follow-up period was evaluated by various questionnaires and evaluation scales.

Description:

After SARS-CoV-2 infection, the patient's immune system is overactivated. While the immune cells release a large number of proinflammatory factors, anti-inflammatory response starts at the same time. Anti-inflammatory factors such as interleukin 4 (IL-4), interleukin 10 (IL-10) and interleukin 37 (IL-37) will be compensated to resist the release of proinflammatory factors and prevent the further development of systemic inflammatory response. However, when the anti-inflammatory factor is excessively released, it will cause compensatory response syndrome, leading to immunosuppression. Whether the level of anti-inflammatory factors continues to rise, and whether it will lead to the persistence of later immunosuppression is unknown. Therefore, this study intends to recruit patients infected with novel coronavirus to enter the hospital within one week of onset, and collect 10ml of patients' blood on the first, seventh, fourteenth and twentieth day after the patients feel the hospital feeling, respectively, to detect the blood inflammatory factors, immune related molecules and immune cells, and determine the changes of patients' immune status. The patients were followed up for 2 and 6 months after arriving at the hospital to conduct self-reported symptom questionnaire, health related quality of life (HRQoL) questionnaire, Hospital Anxiety and Depression Scale (HADS), and other questionnaires and scales to assess the impact of changes in the patient's immunological status on the prognosis and later quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 31, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients diagnosed as novel coronavirus infection by PCR or antigen rapid detection for the first time

2. Patients hospitalized within one week after the occurrence of clinical symptoms related to novel coronavirus infection (fever, cough, shortness of breath or dyspnea, fatigue, headache, muscle or body pain, sore throat, nasal congestion or runny nose, chills, nausea, vomiting, diarrhea, mental state changes)

3. Age over 18, gender unlimited

Exclusion Criteria:

1. Patients with immunosuppression, including HIV infection, hematopoietic stem cell transplantation and high-dose immunosuppressant therapy

2. Patients with severe autoimmune diseases

3. Patients receiving chemotherapy or cancer treatment

4. Pregnancy or breastfeeding

Related Conditions & MeSH terms

• COVID-19
• Immunity
• Life Quality

Intervention

Diagnostic Test:
• hospitalized patient
Collect the patient's whole blood for testing

Locations

Country	Name	City	State
China	Qilu Hospital of Shandong University	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the concentration of inflammatory markers (IL-1ß?IL-2? IL-2R ?IL-4 ? IL-6 ? IL-8? IL-10 ? interferon-gamma(IFN-?)?tumour necrosis factor alpha(TNF-a) ?vascular endothelial growth factor(VEGF), etc.) in peripheral blood.		1, 7, 14, 20 days after the patient arrives at the hospital
Primary	Changes in the concentration of immunosuppression makers(HLA-DR, Programmed Cell Death Ligand 1 (PD-1), T cell immunoglobulin and mucin domain 3(TIM-3),etc.) in peripheral blood.		1, 7, 14, 20 days after the patient arrives at the hospital
Primary	Changes in the number of immune cells(Th1/Th2 cell, Treg cell, Myeloid-derived suppressor cells,etc.) in peripheral blood.		1, 7, 14, 20 days after the patient arrives at the hospital
Secondary	self-reported symptom		2,6 months after the patient arrives at the hospital
Secondary	health related quality of life (HRQoL) questionnaire,	There are five dimensions, each with a minimum value of 1 and a maximum value of 3, and the higher score mean a worse outcome	2,6 months after the patient arrives at the hospital
Secondary	Hospital Anxiety and Depression Scale (HADS)	There are two dimensions, each with a minimum value of 0 and a maximum value of 21,and higher score mean a worse outcome	2,6 months after the patient arrives at the hospital